NCT05775939Recruiting
PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
PET Functional Imaging to Evaluate Cardiac Radiation Damage (EUCLID)
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 7 Feb 2023
- Start date
- 20 Jan 2023
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- Thomas Jefferson University
- Diseases
- Lung cancer, Gastric and esophageal cancer
- NCT number
- NCT05775939
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 20 Jan 2023 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist
- Palliative radiation doses defined as 20 Gy in 5 fractions
Who the study is looking for
- Provide signed and dated informed consent form
- Willing to comply with all study procedures and be available for the duration of the study
- Male or female, aged \>= 18
- Life expectancy \>= 3 months as assessed by Radiation Oncologist
- Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose)
- Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer
- Planned radiation treatment course for management of lung or esophageal cancer \* Both standard and hypofractionation schedules are permitted
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Thomas Jefferson University Hospital Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.